Clinical trial · Observational
An Observational Study of Adherence to Anastrozole in Early Breast Cancer Treatment
An Observational Study of Adherence to Adjuvant Anastrozole Therapy in Postmenopausal Patients With Early Breast Cancer Over One Year Follow-up.
NCT00737009CI-TRIAL-00005051completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to describe adherence to anastrozole treatment current practice: cases where anastrozole treatment was halted ( timescale and causes) and estimate the proportion of postmenopausal women with early breast cancer who continue anastrozole therapy after one year follow-up.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To describe adherence to anastrozole treatment current practice: cases where anastrozole treatment was halted ( timescale and causes)
- timeFrame
- every 3- 6 months (4 visit in one year)
Secondary outcomes (4)
- measure
- Estimate the proportion of postmenopausal women with early breast cancer who continue anastrozole therapy after one year follow-up
- timeFrame
- every 3- 6 months (4 visit in one year)
- measure
- Identify predictors of non- adherence
- timeFrame
- every 3- 6 months (4 visit in one year)
- measure
- The proportion of DFS after 1 year follow-up
- timeFrame
- every 3- 6 months (4 visit in one year)
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Postmenopausal woman with early breast cancer who are prescribed with anastrozole as adjuvant endocrine therapy under the routine clinical practice. * Histologically or cytologically proven to be HR+(ER or PR +) * No other concomitant endocrine therapy such as estrogen therapy or selective estrogen receptor modulators * Provision of written informed consent Exclusion Criteria: * Recurrence of breast cancer * Known hypersensitivity to anastrozole or to any of its excipients * Any severe concomitant condition which makes it undesirable for the patient to participate in the trial or which would jeopardize adherence with the trial protocol: Amenorrhea\<12 months and a intact uterus; Previous inclusion in the present study; Participation in a other clinical study during the last 30 days· * Women who does not agreed to participate the program
References
Publications (0)
Data not yet available
No reference posted for this study.